<DOC>
	<DOC>NCT00254254</DOC>
	<brief_summary>This study will be the first evaluation of exenatide in adolescent subjects with type 2 diabetes mellitus and is designed to evaluate the blood levels of the drug (pharmacokinetics), the drug's biochemical and physiological effects (pharmacodynamics), and tolerability of exenatide in these subjects.</brief_summary>
	<brief_title>A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Exenatide in Adolescent Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Treatment with diet and exercise alone or a stable dose of metformin, or sulfonylurea, or metformin plus a sulfonylurea for at least 3 months. Has HbA1c 6.0% to 11.0%, inclusive, at screening. Has a body weight of &gt;= 50 kg at screening. Received any investigational drug or has participated in any type of clinical trial within 3 months prior to screening. Currently participates in any other interventional study. Is currently treated with any of the following excluded medications: Sulfonylurea chlorpropamide Thiazolidinedione within 3 months of screening. Î‘lpha glucosidase inhibitor within 3 months of screening. Meglitinide within 3 months of screening. Insulin within 3 months of screening. Pramlintide within 3 months of screening.</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>diabetes</keyword>
	<keyword>adolescents</keyword>
	<keyword>exenatide</keyword>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
</DOC>